ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
MyMD Pharmaceuticals Inc

MyMD Pharmaceuticals Inc (MYMD)

1.82
0.00
( 0.00% )
Updated: 20:00:00

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.82
Bid
1.78
Ask
1.84
Volume
-
0.00 Day's Range 0.00
1.7501 52 Week Range 63.90
Market Cap
Previous Close
1.82
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
60,796
Shares Outstanding
2,307,632
Dividend Yield
-
PE Ratio
-0.51
Earnings Per Share (EPS)
-3.56
Revenue
-
Net Profit
-8.22M

About MyMD Pharmaceuticals Inc

MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple scleros... MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Show more

Sector
In Vitro,in Vivo Diagnostics
Industry
In Vitro,in Vivo Diagnostics
Website
Headquarters
Baltimore, Maryland, USA
Founded
1970
MyMD Pharmaceuticals Inc is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker MYMD. The last closing price for MyMD Pharmaceuticals was $1.82. Over the last year, MyMD Pharmaceuticals shares have traded in a share price range of $ 1.7501 to $ 63.90.

MyMD Pharmaceuticals currently has 2,307,632 shares outstanding. The market capitalization of MyMD Pharmaceuticals is $4.20 million. MyMD Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.51.

MYMD Latest News

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today

New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (formerly MyMD Pharmaceuticals...

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following...

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and...

MyMD Pharmaceuticals Secures Strategic Investments

Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front MyMD Pharmaceuticals, Inc.® (Nasdaq:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.04-2.150537634411.861.911.7601250881.82044289CS
4-0.04-2.150537634411.862.051.7501206721.82729278CS
12-1.22-40.13157894743.043.36691.7501607962.08241358CS
26-3.58-66.29629629635.45.518471.75013055243.52522923CS
52-27.88-93.872053872129.763.91.750171308213.38574649CS
156-140.68-98.7228070175142.5298.51.750141134348.85197193CS
260-161.08-98.8827501535162.9298.51.750141071657.02590827CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUZENuZee Inc
$ 2.9816
(189.48%)
76.64M
DRMADermata Therapeutics Inc
$ 2.7099
(108.45%)
52.77M
SLNASelina Hospitality PLC
$ 0.0509
(95.77%)
670.74M
QXOQXO Inc
$ 137.07
(72.85%)
76.59k
PIRSPieris Pharmaceuticals Inc
$ 13.58
(70.18%)
4.06M
NXTTNext Technology Holding Inc
$ 1.97
(-66.15%)
320.69k
NUWENewellis Inc
$ 2.60
(-37.35%)
680.87k
ATPCAgape ATP Corporation
$ 0.14
(-34.88%)
4.24M
VWEVintage Wine Estates Inc
$ 0.075
(-32.98%)
17.14M
CONNConns Inc
$ 0.375
(-26.04%)
2.14M
SLNASelina Hospitality PLC
$ 0.051
(96.15%)
670.84M
SGMOSangamo Therapeutics Inc
$ 0.5645
(40.67%)
168.49M
NVDANVIDIA Corporation
$ 118.00
(-3.74%)
81.52M
TSLATesla Inc
$ 217.33
(-11.79%)
77.41M
NUZENuZee Inc
$ 2.9999
(191.25%)
76.64M

MYMD Discussion

View Posts
leifsmith leifsmith 2 days ago
New Name: TNF Pharmaceuticals, Inc. — PR this morning

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. — JULY 22, 2024 9:00AM EDT

* New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system

* Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies

* TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024

https://ir.tnfpharma.com/news-events/press-releases/detail/60/mymd-pharmaceuticals-announces-corporate-rebranding-to-new

This name change makes sense - someone at the company is thinking ...
👍️0
leifsmith leifsmith 2 weeks ago
Interesting PR of 6/17/24: New President and Chief Medical Officer; and new board member

Although there are reasons to doubt the integrity of this company it is possible that this press release means something.

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

https://www.morningstar.com/news/business-wire/20240617357457/mymd-pharmaceuticals-appoints-accomplished-biopharmaceutical-leader-and-current-board-member-mitchell-glass-md-as-president-and-chief-medical-officer

No matter what has failed to happen it is hard to hide the importance of a molecule that can selectively and beneficially regulate TNF-alpha. Ray Blanco was and is right about the science.
👍️0
SeanVan SeanVan 2 weeks ago
Gentlemen!
Can some one please start a class action on this company MYMD.
They reduced 30:1 to 16.6M and now they want to dilute it by increasing up to 250M shares.
All these 3 years, the expenses to this company were negligible. They manipulated stock & accumulated over $100M.

Lets file a Class action law suit on MYMD. The companies that are sincere are having law suits, but this fradulennt company with hight corrupt manipulators must not let go.. This is their 4th company with same kind of fraud.

Check online on APPLE/GOOGLE class action suits and follow same on this ASAP.
👍️0
critical_perspective critical_perspective 1 month ago
So now Chapman has jumped ship? The writing was already on the wall. If the research/progress on mymd-1 was/is so promising, then why leave? Chapman's "leadership" was suspect when he became involved with MIRA and TELO. Even with the new 'well-qualified outsider' and new President/CMO Mitchell Glass, I wonder if this is yet another one of Williams' revolving door ploys, replete with smoke and mirrors? Time will tell, but I don't think this bodes well for investors interested in the scientific (and marketable) promise of the company!
👍️ 1
tw0122 tw0122 2 months ago
Boom boom pump to $3s dump to $2s
👍️0
leifsmith leifsmith 2 months ago
MyMD Pharmaceuticals Secures Strategic Investments, May 21 2024 - 9:00AM

Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front

https://ih.advfn.com/stock-market/NASDAQ/mymd-pharmaceuticals-MYMD/stock-news/93897525/mymd-pharmaceuticals-secures-strategic-investments
👍️0
deast deast 2 months ago
As of March 30, 2024 Mirae Asset Global Investment Ltd. holds 875,933 shares (40%) of MYMD? This was posted on another board. Anyone know if this is true?
👍️0
critical_perspective critical_perspective 3 months ago
Leif, I think abandonment is an appropriate term. I think the actions of MYMD's (now former) employee Adam Kaplin -- and the company's silence in the 8K -- speaks volumes. When will Chapman jump ship? Is the company's behavior ---which appears full of impropriety -- "just" negligent... or is it criminal? Whatever it is, it certainly is questionable!
👍️0
deast deast 3 months ago
8K filed by MYMD April 15, 2024, Adam Kaplan, Chief Scientific Officer resigned.
👍️0
leifsmith leifsmith 3 months ago
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug

https://www.biospace.com/article/releases/telomir-pharmaceuticals-unveils-compelling-pre-clinical-data-on-age-reversal-drug-telomir-1-at-national-press-club-event-in-washington-d-c-/

Question: Is Telomir-1 the successor of MYMD-1, discovered by the same people, who are now running Telomir Pharmaceuticals?

Have MYMD investors been totally abandoned while the best discoveries have been homed in a new company?

An unpleasant question to ask. I hope to be proven wrong.
👍️0
SeanVan SeanVan 3 months ago
I have been monitoring the pattern of MYMD stocks performance for the past 3 years.... They have bear group/Black pool internal group under Chairman Silverman who does reduce the stock during all good news intentionally. They dont want the fruits to go to investors buy all of their internal known group of people. Whatever happened reflects 100% manipulation like "star scientific" & Rock creek Pharma repetition.
👍️ 1
SeanVan SeanVan 3 months ago
My understannding is that: The 62M stocks reduced to 2.1M and now they want to add/dilute this again upto 62M stocks (12M Common & 50M Preferred Stock) in future by selling to various investors. Its all BIG manipulation.
👍️0
critical_perspective critical_perspective 3 months ago
I think it's more smoke and mirrors. (Hope I'm wrong). They sure do a great job of creating the impression they are serious... too much flash 'n fluff... However, we need something concrete other than promises, allusions, and illusions. Completed studies with attendant full reports noting clear & significant findings which either lead to partnerships or to market would help!!
👍️ 2
leifsmith leifsmith 3 months ago
From the 8-K just filed: https://ir.mymd.com/sec-filings/all-sec-filings##document-1028-0001493152-24-013870-1

Bio of Dr. Mitchell Glass (from https://www.medproinvestors.com/team; out of date probably)

Dr. Mitchell Glass is a 25 year veteran of the pharmaceutical industry.
His experience includes senior positions at top ten pharmaceutical companies,
as well as investment in and management of start-ups and biotechs.
 
After seven years of research, teaching and patient care at the University of Pennsylvania, Dr. Glass joined ICI Pharmaceuticals in 1988 where he established the pulmonary therapeutics group and led the development and submission of the antileukotriene ACCOLATE®. From 1995 to 1996, Dr. Glass was Vice President and Director at SmithKline Beecham where he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialization, including submission of the NDA/MAA for COREG®. From 1998 to 2003, Dr. Glass was Chief Medical Officer and VP of Clinical Development and Regulatory Affairs of AtheroGenics Inc. (AGIX), where he led product development from IND to initiation of Phase 3 for AGI1067 and was a member of the IPO team. Dr. Glass later joined AQUMEN Biopharmaceuticals KK and NA as CEO of AQUMEN NA and currently serves as Executive VP R&D and Chief Medical Officer of Invion Limited. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.

***

I have no idea what any of this 8-K signifies. Maybe tells us some preferred stock can be converted to common on terms specified in subsidiary documents.
👍️ 1
critical_perspective critical_perspective 4 months ago
The primary target for Telomir -- age reversal -- just so happens to align with MYMD's primary target of sarcopenia. Coincidence? I haven't been able to see the actual makeup of Telomir-1 but, like you, I suspect its development is directly linked to the research done for MYMD-1. Why haven't the full results from the sarcopenia study (which ended early June 2023) been published yet? The Annual Report just came out the other day and it does not inspire confidence. Actually, from what I can make of it, it looks quite disappointing... especially with the departure of key individuals. In addition, the lack of communication from the company is disturbing, and in light of everything else, rather alarming.

For those of us who were invested in Williams' previous ventures (i.e. Star Scientific, Rock Creek), this behavior of questionable actions (to say the least) unfortunately appears to be his M.O. He found a compelling means of raising significant capital and then leaving investors dry. I don't have a good feeling about any of it. It is indeed very unfortunate, because the product(s) and the research behind them were truly promising and significant!
👍️ 1
leifsmith leifsmith 4 months ago
Previous msg posted twice. No idea why.
👍️0
leifsmith leifsmith 4 months ago
I've noticed that migration. I wonder if the Telomir drug is a direct descendent of MYMD-1. If so, it seems that it should have been kept in MYMD for the benefit of MYMD's investors. Is it the case that they came up with something of extraordinary potential and decided to move it out of MYMD, abandoning the investors there, and put it into a new company to benefit a new group of investors? I hope this is not what's going on, but in the absence of communication from the company we can have no idea.
👍️ 1
Monksdream Monksdream 4 months ago
MYMD under $3
👍️0
Regis999 Regis999 4 months ago
Do you know if people on this board were involved in this Scheme?
Notice how they have disappeared !!!!


"The day one of Reverse merger of MYMD with AKERS, the MYMD stock started plummeting. If you carefully monitor the trends of MYMD Stock fluctuations its always down whether you see positive news or not. This continuous manipulation is for a reason... probably bankrupt MYMD and sell this company to a Big pharma for a few Billions. Jonnie did same with Star Scientific & Rock Creek pharma. He ditched millions of sincere investors. I clearly see that he will do one more reverse split to keep the investors away and bankrupt and then sell the company for a great price as it has cleared Phase-2."
👍️0
SeanVan SeanVan 4 months ago
The day one of Reverse merger of MYMD with AKERS, the MYMD stock started plummeting. If you carefully monitor the trends of MYMD Stock fluctuations its always down whether you see positive news or not. This continuous manipulation is for a reason... probably bankrupt MYMD and sell this company to a Big pharma for a few Billions. Jonnie did same with Star Scientific & Rock Creek pharma. He ditched millions of sincere investors. I clearly see that he will do one more reverse split to keep the investors away and bankrupt and then sell the company for a great price as it has cleared Phase-2...
👍️ 1
critical_perspective critical_perspective 4 months ago
Anyone care to share their thoughts on this? It appears that Chris Chapman and Adam Kaplin have key roles in two more of Jonnie's new ventures: MIRA Pharma and Telomir Pharma. Until very recently Adam Kaplin was President and Chief Scientific Officer of MIRA Pharmaceuticals while Chapman was their CEO & Chairman of the Board. Now they are both gone from MIRA (or have greatly reduced roles) and have taken up new positions at Telomir

My question is: what about MYMD?? How can anyone expect to have any confidence in them or in the company when they do something like this?? Shouldn't they be devoting their time and energies to advancing the research and interests of MYMD?Is this even ethical? No wonder why the share value has been and is plummeting! Is this just another one of Jonnie's schemes? What do you all think?
👍️ 1
Regis999 Regis999 5 months ago
"Hopefully, Williams gets it right this time." Not this time................
👍️ 1
Regis999 Regis999 5 months ago
30 for 1 Reverse Split is not a positive event. All investors are under water.
👍️ 1
deast deast 5 months ago
Please remain under your rock and refrain from your annoying nonsense.
👍️0
Regis999 Regis999 5 months ago
Williams is one of the worse business men on the planet.
👍️ 1
Monksdream Monksdream 5 months ago
MYMD new 52 week low
👍️0
Regis999 Regis999 5 months ago
Pathetic !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Williams strikes again
👍️ 1
Renee Renee 5 months ago
MYMD: effective Feb. 15,2024 a one for 30 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
👍️0
SeanVan SeanVan 5 months ago
check this out.. about MyMD founder

https://www.newsweek.com/2014/01/24/funny-money-man-behind-mcdonnells-fall-245100.html
👍️0
SeanVan SeanVan 5 months ago
I have been telling in this board to all since many months that.... The Chairman of the Board Josh Silverman came from AKERS who is expert inn manipulation of the stocks... Now 30:1 reverse split will happen tomorrow, which reduces to shares 2,091,638. Important to note that, they already got approval from NASDAQ to add upto 16M new stocks if needed. This so called manipulators MyMD Founder Johnnie W, & Silverman add those remaining shares in short time which dilutes the value by saying Phase 3 purposes. This company is living on all frauds. What do you say?
👍️0
deast deast 5 months ago
Reverse split. 30 to 1.
👍️ 1
SeanVan SeanVan 6 months ago
Nasdaq Delisting of MYMD Notice as expected by Many sincere investors:
.
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=317802932&type=HTML&symbol=MYMD&cdn=d11231e10863bcbb58b0c4d4615e2222&companyName=MyMD+Pharmaceuticals+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2023-10-13
👍️0
deast deast 6 months ago
I hope they find a partner because the hacks at the SEC might not be able to distinguish a naked short from a flasher. Just my humble opinion.
👍️0
B and B B and B 6 months ago
Not until the sec sends the naked short to prison or the company finds a partner. It’s a zero or 100+ dollar stock Make your bet at least I know my downside
👍️0
Regis999 Regis999 6 months ago
New low at $ .165 on HUGE volume Will the selling ever end?
👍️0
leifsmith leifsmith 6 months ago
Canadian patent 3013634 granted

Abstract: "In one aspect, a method of increasing hair growth includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle therefor. In another aspect, a method of improving the appearance of hair includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor."

isomyosmine (MYMD-1) is interestingly versatile.

Near the close the price went as high as 0.21 on over 3,200,000 shares, then collapsed to 0.17 on much lower volume, closing at 0.203. After hours 0.18 seems to be popular. Hair raising, if you care. I don't much. This announcement means little, far as I can tell.
👍️0
Regis999 Regis999 6 months ago
New 52 week low on huge volume--down trend continues
👍️0
leifsmith leifsmith 7 months ago
I don't know about Ray Blanco's current list. Read something by him many months ago. He was right then, and still right now about the science. But badly wrong about a good time to buy.
👍️ 1
tschussmann1 tschussmann1 7 months ago
Nice to see someone that remembers Anatabloc…I too found it useful. Would be great if isomyosmine was “next generation”. I had seen that Ray Blanco was covering MYMD while it was still a $2 stock, but I had not seen it covered more recently…at least in the publications I had a subscription to. He still has it on a current list?
👍️ 1
stockyupydowny stockyupydowny 7 months ago
"If approved, MYMD-1 could become the first FDA-approved drug for sarcopenia, which causes patients to have a decline in muscle mass, among other symptoms.

MyMD Pharmaceuticals has already submitted and been approved for three Investigational New Drug Applications for MYMD-1. The company is advancing these clinical programs in chronic inflammatory conditions, including sarcopenia, rheumatoid arthritis and Hashimoto's disease, an often genetic disorder that causes inflammation of the thyroid gland.
👍️ 1
makinezmoney makinezmoney 7 months ago
$MYMD: WOAAAAahhhhhhhhhhhh whatta pop. now $0.30


That was a big suprise from 0.22

NICEEEEEEEEeeeeeeeeeeeeeee



GO $MYMD
👍️0
stockyupydowny stockyupydowny 7 months ago
Solid News https://www.accesswire.com/820920/mymd-pharmaceuticals-releases-positive-clinical-trial-results-for-sarcopenia-treatment-drug
👍️ 1
stockyupydowny stockyupydowny 7 months ago
Buy out.... ?
👍️0
leifsmith leifsmith 7 months ago
I don't agree. My friends, employees, and I had direct experience with Anatabloc, a product of William's Star Scientific. The anatabine-citrate molecule was the real thing. The benefits were remarkable. People homebound with Crohn's disease were set free.

Now, there is evidence that the isomyosmine molecule, MYMD-1, is an improvement on anatabine-citrate.

The article linked should be treated with suspicion as a possible "hit piece". There were political currents involving Bob McDonnell's race for governor of Virginia. Williams got swept up in those currents and a letter was issued by the FDA (trust them? no) that destroyed his company and injured McDonnell.

The molecule being developed by Williams and his collaborators at Johns Hopkins is both a threat and an opportunity for major pharma companies currently earning large revenues from the sale of biologics.

MYMD-1 does everything the leading biologics (Enbrel, Humira) do, but better and without the serious side effects. They are biological sledge hammers, MYMD-1 is a jewelers hammer.

Ray Blanco's assessment is correct.
👍️ 2
B and B B and B 7 months ago
How many times how many message boards you going to post the same thing. I will add tomorrow Thanking you
👍️ 2 😎 1 🤫 1
SeanVan SeanVan 7 months ago
This article must be read by every one.. Please share this.
This is not the first time Jonnie is doing this kind of fraud, its almost 4th time ... same kind, with same Chris Chapman...From Starscientific to Rockcreek Pharma to MyMD Pharma... Jonnie manipulated (with some crooks like Silveman) all these stocks into Penny stocks. He will never change and he is living on innocent investors blood. Very unethical, inhumane.... Its nothing but unpardonable financial crime if any investigation takes palce. Please note...

https://www.newsweek.com/2014/01/24/funny-money-man-behind-mcdonnells-fall-245100.html
👍️0
sheepsandgoats sheepsandgoats 7 months ago
Take any profits you can by close tomorrow (best by close today). I believe shorts are closing and taking end year profits. Something to consider. Other thoughts for over 10M shares trading in less than 2 days, let's hear it.
👍️0
stockyupydowny stockyupydowny 7 months ago
Perhaps the buyout is taking place ..... this is well worth over $1 minimum ..... continuation into tomorrow?
👍️0
nathanial nathanial 7 months ago
Going crazy after hours. Last trade 0.43. Huge volume.
👍️0
sheepsandgoats sheepsandgoats 7 months ago
I'm inclined to agree.
👍️0